Fig. 6: Molecular pathways underlying the role of Foxm1 in LSCs.

a Heat map of the expression of 546 Foxm1-regulated genes upregulated (red) or downregulated(green) twofold or more (P ≤ 0.05) in LSCs from Foxm1-KO MA9-leukemia mice (MA9-Foxm1-KO-LSCs) relative to LSCs from MA9-leukemia mice (MA9-Foxm^fl/fl LSCs). b Pie charts show the distribution of 546 genes which are differentially expressed in Foxm1-deficinet and control LSCs into functional groups. c Quantitative RT-PCR analysis of selected genes in LSCs; results were normalized to those of Actb and are presented relative to those of Foxm1^fl/fl control LSCs. d–e Gene-set-enrichment analysis of selected gene sets (12,000 transcripts) encoding products related to DNA repair pathways (d), the Wnt/β-catenin signaling (e, top) or that are targeted by c-Myc (e, bottom), presented as enrichment score as well as genes “positively correlated” with Foxm1 deficiency (KO > WT) or “negatively correlated” with Foxm1 sufficiency (WT > KO) in MA9-LSCs. d, P < 0.0001; e top, P < 0.001; e bottom; P < 0.001. f Western Blot analysis of Foxm1 and β-catenin expression in primary leukemia cells from MA9-foxm1^fl/fl (control) and MA9-Foxm1-CKO mice. g Western Blot analysis of FOXM1 and β-CATENIN expression in human leukemia cells with expression of MLL fusion genes. The cells were treated with 40 μM FOXM1-specific peptide or mutant peptide. h Western Blot analysis of FOXM1 and β-CATENIN expression in MV4-11 human leukemia cells with expression of FOXM1 or control vector. i Co-immunoprecipitation assay of endogenous β-CATENIN and FOXM1 in MV4-11 human leukemia cell lines. j Western Blot analysis of Foxm1 and β-catenin in BM cells from MA9-Foxm1^fl/fl and MA9-Foxm1 CKO leukemia mice. The cells were treated with 20 μM MG132 or DMSO for 6 h, *p < 0.05, **p < 0.01, ***p < 0.001, mean ± s.d., t-test. Source data are provided as a Source Data file.